Curaleaf Holdings (CURLF) Change in Account Payables (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Change in Account Payables of -$10.0 million for Q4 2024, down 153.26% year-on-year from $18.7 million in Q1 2024, and up 20.19% on a QoQ basis from -$12.5 million in Q3 2024.
Curaleaf Holdings (CURLF) Change in Account Payables (2019 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Change in Account Payables for 6 consecutive years, with -$10.0 million the latest figure, recorded in Q4 2024.
- Quarterly Change in Account Payables fell 153.26% year-over-year to -$10.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$18.6 million (down 218.68% YoY) and the FY2025 annual result came in at -$5.2 million, up 7.76% from the prior year.
- Change in Account Payables grew to -$10.0 million in Q4 2024 per CURLF's latest filing, from -$12.5 million in the prior quarter.
- Over the last five years, Change in Account Payables for CURLF reached as high as $35.8 million in Q1 2022 and fell as low as -$14.9 million in Q3 2023.
- A 5-year average of $1.9 million and a median of -$289000.0 in 2021 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables jumped 12179.39% — and 2023, when it sank 222.14%.
- Year by year, Change in Account Payables stood at $15.2 million in 2020, then sank by 155.18% to -$8.4 million in 2021, then jumped by 96.64% to -$282000.0 in 2022, then jumped by 6726.95% to $18.7 million in 2023, then tumbled by 153.26% to -$10.0 million in 2024.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$10.0 million, -$12.5 million, and $18.7 million for Q4 2024, Q3 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -9.95 Mn |
| Dec 31, 2024 | -9.95 Mn |
| Sep 30, 2024 | -12.47 Mn |
| Sep 30, 2024 | -12.47 Mn |
| Dec 31, 2023 | 18.69 Mn |
| Dec 31, 2023 | 18.69 Mn |
| Sep 30, 2023 | -14.90 Mn |
| Sep 30, 2023 | -14.90 Mn |
| Dec 31, 2022 | -282,000.00 |
| Dec 31, 2022 | -282,000.00 |
| Sep 30, 2022 | 12.20 Mn |
| Sep 30, 2022 | 12.20 Mn |
| Jun 30, 2022 | 2.42 Mn |
| Jun 30, 2022 | 2.42 Mn |
| Mar 31, 2022 | 35.76 Mn |
| Mar 31, 2022 | 35.76 Mn |
| Dec 31, 2021 | -8.40 Mn |
| Dec 31, 2021 | -8.40 Mn |
| Sep 30, 2021 | 2.62 Mn |
| Sep 30, 2021 | 2.62 Mn |